Navigation Links
Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference
Date:1/3/2008

CRANBURY, N.J., Jan. 2 /PRNewswire-FirstCall/ -- Amicus Therapeutics Inc. (Nasdaq: FOLD), today announced that John F. Crowley, President and Chief Executive Officer, will present a corporate update at the 26th Annual JPMorgan Healthcare Conference in San Francisco, CA on Monday, January 7, 2008 at 11:30 am (Pacific Standard Time) at the Westin St. Francis Hotel.

The presentation will be webcast live and may be accessed by visiting Amicus' website at http://www.amicustherapeutics.com. A replay of the webcast will also be available on the Company's website until January 22, 2008.

About Amicus Therapeutics

Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of Amigal(TM) for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera(TM) for the treatment of Gaucher disease. The Company has completed Phase 1 clinical trials of AT2220 for the treatment of Pompe disease.

Forward-Looking Statements

Amicus cautions you that statements included in this press release that are not a description of historical facts are "forward-looking statements" within the meaning of Section 21E of the Private Securities Litigation Reform Act of
'/>"/>

SOURCE Amicus Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
2. Amicus Therapeutics Announces Plans to Present Phase 1 Data for AT2220 for Pompe Disease
3. Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease
4. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
5. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
6. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
7. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
8. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
9. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
10. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
11. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... 2014  Heated dialogue in recent months about the ... treatments to Gilead,s new hepatitis C drug Harvoni® – ... questioning what it means to put a price on ... And while drug pricing is one of the most ... a general business and ethical standpoint – it is ...
(Date:11/21/2014)... 2014 Clementia Pharmaceuticals, Inc. ... (EMA) has granted Orphan Medicinal Product Designation ... for the treatment of fibrodysplasia ossificans progressiva ... genetic disease characterized by painful, recurrent episodes ... abnormal bone formation. This process, known as ...
(Date:11/21/2014)... Nov. 20, 2014 /PRNewswire/-- CANTEL MEDICAL CORP. (NYSE: CMN ... Executive Officer, will be presenting at the 26 th ... Hotel in New York . The formal ... PM ET. In addition, Mr. Krakauer and Jorgen B. ... one-on-one meetings during the day. An audio ...
Breaking Medicine Technology:"The Price of Global Health" Tackles Worldwide Drug-Pricing Debate 2"The Price of Global Health" Tackles Worldwide Drug-Pricing Debate 3"The Price of Global Health" Tackles Worldwide Drug-Pricing Debate 4"The Price of Global Health" Tackles Worldwide Drug-Pricing Debate 5Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 2Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 3
... AstraZeneca (NYSE: AZN ) announced today that Judge Joseph ... that the substance patent protecting CRESTOR (RE37,314 – the ,314 patent) is valid ... committed by any Shionogi employee. The court also held the ,314 patent to ... , , ...
... June 29 Dr. Harry J. Guttman, Esq. , Of ... participant at the 2010 Central Regional Meeting of the American Chemical Society ...  The 2010 CeRMACS attracted over 400 participants and focused on small business ... , , ...
Cached Medicine Technology:CRESTOR® Patent Upheld By US Court 2CRESTOR® Patent Upheld By US Court 3Dr. Harry J. Guttman, Esq. Invited Speaker at 2010 Central Regional Meeting of the American Chemical Society 2
(Date:11/22/2014)... wide variety and complexity of foods served at holiday ... allergies, an expert warns. "Every person is different ... that it can be really difficult to avoid all ... allergy and clinical immunology at Wake Forest Baptist Medical ... you know you have food allergies, caution should overrule ...
(Date:11/22/2014)... 22, 2014 Hastings and Hastings, a ... experience announces providing clients with the option of leaving ... clients a flexible, intuitive and easy to navigate website ... access to Google + allows clients to research the ... a more informed decision when retaining an attorney. Those ...
(Date:11/22/2014)... 2014 Sandbridge Capital, a private ... the consumer brand sector, acquired a minority stake ... used to help fund BackJoy’s global growth and ... its proprietary apparel and footwear lines. Sandbridge Capital ... of Directors. , BackJoy is a high-growth health ...
(Date:11/22/2014)... November 22, 2014 Wright & Schulte ... side-effects lawsuits have been scheduled between October 2016 ... District of Illinois. U.S. District Judge Matthew F. Kennelly, ... Case Management Order (CMO) on November 6, 2014 that ... attorneys to submit documents and other activities in preparation ...
(Date:11/22/2014)... Those air-blown hand dryers in public restrooms may spread ... study suggests. British researchers placed a harmless type ... to simulate poorly washed hands. They then had them ... to dry their hands. The investigators measured airborne ... both types of dryers than around towel dispensers. ...
Breaking Medicine News(10 mins):Health News:'Tis the Season of Challenges for Those With Food Allergies 2Health News:Hastings and Hastings Announces Providing Clients with the Option of Leaving an Online Review Using Google + 2Health News:Hastings and Hastings Announces Providing Clients with the Option of Leaving an Online Review Using Google + 3Health News:Sandbridge Capital Acquires a Minority Stake in BackJoy 2Health News:Sandbridge Capital Acquires a Minority Stake in BackJoy 3Health News:First Bellwether Trials Scheduled In AndroGel Side-Effects Lawsuits Reports Wright & Schulte LLC 2Health News:First Bellwether Trials Scheduled In AndroGel Side-Effects Lawsuits Reports Wright & Schulte LLC 3Health News:First Bellwether Trials Scheduled In AndroGel Side-Effects Lawsuits Reports Wright & Schulte LLC 4Health News:Restroom Hand Dryers Spread More Germs Than Paper Towels, Study Finds 2
... Health Management Systems,Inc. (HMS) announced today that it ... in Medford, Massachusetts, to provide coordination of,benefits services. ... than 150,000 MassHealth and Commonwealth Care members across,Massachusetts., ... will identify third party coverage for claims already ...
... CHARLOTTE, N.C., Dec. 12 CG Technology has ... better reflecting the depth,and breadth of services it ... high quality and standards of work, while focusing ... Carlisle & Gallagher Consulting Group (CG) is a ...
... 12 ATS Medical, Inc.,(Nasdaq: ATSI ), ... services, today announced that James L. Cox, M.D. ... Dr. Cox, reputation as a,preeminent authority in the ... that serves as the foundation for ATS 3f(R),tissue ...
... to six community organizations in ... underserved areas, WOODLAND HILLS, ... a total of $30,000 in end of,year donations to various food banks ... agencies in northern and,southern California to assist vulnerable populations., Blue Cross ...
... An improved understanding of the effects of regulation ... designed to advance entrepreneurship, according to a new ... for Entrepreneurship Public Policy report provides an overview ... system can discourage or encourage the entrepreneurial spirit. ...
... Dec. 11 Biodel Inc. (Nasdaq:,BIOD) today reported ... financial results, updated pipeline progress and disclosed 2008,objectives., ... public company, we advanced our pipeline,and achieved critical ... of Biodel. "The significant milestones reached include our,successful ...
Cached Medicine News:Health News:Network Health Awards Contract to HMS for Coordination of Benefits 2Health News:ATS Medical Appoints James L. Cox, M.D. as Medical Director 2Health News:ATS Medical Appoints James L. Cox, M.D. as Medical Director 3Health News:Blue Cross of California Gives $30,000 in Holiday Donations to Food Banks Throughout the State 2Health News:Rand study examines the effect of policy on entrepreneurship and small businesses 2Health News:Biodel Inc. Reports Fourth Quarter and Fiscal Year 2007 Financial Results 2Health News:Biodel Inc. Reports Fourth Quarter and Fiscal Year 2007 Financial Results 3Health News:Biodel Inc. Reports Fourth Quarter and Fiscal Year 2007 Financial Results 4Health News:Biodel Inc. Reports Fourth Quarter and Fiscal Year 2007 Financial Results 5Health News:Biodel Inc. Reports Fourth Quarter and Fiscal Year 2007 Financial Results 6Health News:Biodel Inc. Reports Fourth Quarter and Fiscal Year 2007 Financial Results 7Health News:Biodel Inc. Reports Fourth Quarter and Fiscal Year 2007 Financial Results 8Health News:Biodel Inc. Reports Fourth Quarter and Fiscal Year 2007 Financial Results 9
S-ROM acetabular cups provide a variety of geometrical options to help address many anatomical situations and defects....
S-ROM acetabular cups provide a variety of geometrical options to help address many anatomical situations and defects....
The Trident ceramic acetabular system provides several important benefits and meets greater demands of younger, more active patients....
Optimal solution for normal acetabulum and younger patients....
Medicine Products: